| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ZNF689 |
| Uniprot No | Q96CS4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-500aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSMAPPSAP LPAQGPGKAR PSRKRGRRPR ALKFVDVAVY FSPEEWGCLR PAQRALYRDV MRETYGHLGA LGCAGPKPAL ISWLERNTDD WEPAALDPQE YPRGLTVQRK SRTRKKNGEK EVFPPKEAPR KGKRGRRPSK PRLIPRQTSG GPICPDCGCT FPDHQALESH KCAQNLKKPY PCPDCGRRFS YPSLLVSHRR AHSGECPYVC DQCGKRFSQR KNLSQHQVIH TGEKPYHCPD CGRCFRRSRS LANHRTTHTG EKPHQCPSCG RRFAYPSLLA IHQRTHTGEK PYTCLECNRR FRQRTALVIH QRIHTGEKPY PCPDCERRFS SSSRLVSHRR VHSGERPYAC EHCEARFSQR STLLQHQLLH TGEKPYPCPD CGRAFRRSGS LAIHRSTHTE EKLHACDDCG RRFAYPSLLA SHRRVHSGER PYACDLCSKR FAQWSHLAQH QLLHTGEKPF PCLECGRCFR QRWSLAVHKC SPKAPNCSPR SAIGGSSQRG NAH |
| 预测分子量 | 59 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ZNF689重组蛋白的虚构参考文献示例(内容基于典型研究场景模拟，非真实文献)：
1. **文献名称**: "ZNF689重组蛋白在白血病细胞中的促癌机制研究"
**作者**: Zhang L, et al.
**摘要**: 本研究通过构建ZNF689重组蛋白，发现其在急性髓系白血病(AML)细胞中高表达，并通过调控DNA损伤修复通路增强白血病细胞的化疗耐药性。体外实验表明，重组ZNF689蛋白可结合BRCA1启动子区域，抑制其转录活性。
2. **文献名称**: "ZNF689重组蛋白的功能鉴定及其与端粒酶活性的关联"
**作者**: Wang Y, et al.
**摘要**: 该研究利用大肠杆菌表达系统纯化ZNF689重组蛋白，证实其C末端锌指结构域具有特异性DNA结合能力。进一步实验显示，ZNF689通过激活hTERT启动子促进端粒酶活性，可能与肿瘤细胞永生化相关。
3. **文献名称**: "ZNF689重组蛋白在肝细胞癌转移中的调控作用"
**作者**: Chen H, et al.
**摘要**: 通过原核表达获得高纯度ZNF689重组蛋白，研究发现其可增强HepG2细胞的迁移和侵袭能力。机制研究表明，ZNF689与HIF-1α相互作用，协同激活EMT通路，促进肝癌转移。
4. **文献名称**: "ZNF689重组蛋白的晶体结构解析及其功能域分析"
**作者**: Gupta R, et al.
**摘要**: 本研究首次报道了ZNF689重组蛋白的X射线晶体结构(分辨率2.1Å)，揭示了其锌指结构域的特殊折叠模式。结合突变实验，证实第4锌指模体为关键DNA结合区域，为靶向药物设计提供结构基础。
注：以上内容为模拟生成，实际文献需通过PubMed/Google Scholar等平台检索确认。
ZNF689 is a member of the zinc finger protein family, characterized by conserved C2H2-type zinc finger domains that facilitate DNA binding or protein-protein interactions. It functions as a transcription factor or epigenetic regulator, influencing gene expression programs involved in cell differentiation, proliferation, and apoptosis. Initially identified through genomic studies, ZNF689 has gained attention for its role in hematopoiesis and cancer, particularly in myeloid malignancies such as acute myeloid leukemia (AML). Research suggests it may act as a tumor suppressor by modulating pathways like the DNA damage response or by repressing oncogenic transcription factors. For instance, ZNF689 interacts with BCL6. a key regulator in lymphocyte development, hinting at its broader role in maintaining genomic stability and cellular homeostasis.
Recombinant ZNF689 protein is engineered using expression systems (e.g., E. coli or mammalian cells) to produce purified, functional protein for experimental studies. It typically includes affinity tags (e.g., His-tag) for simplified purification and detection. This tool enables in vitro analyses, such as binding assays to map DNA targets or protein interaction partners, structural studies to elucidate its functional domains, and high-throughput screens for compounds that modulate its activity. Additionally, recombinant ZNF689 aids in antibody development and mechanistic studies exploring its tumor-suppressive functions. Ongoing research aims to clarify its regulatory networks and therapeutic potential, positioning ZNF689 as a promising target for precision oncology strategies in hematologic cancers.
×
